Ringpu Bio-Technology wins first China mRNA vaccine approval

Ringpu Bio-Technology has secured clinical trial approval from the Ministry of Agriculture and Rural Affairs for its swine epidemic diarrhea virus mRNA vaccine. This marks the first clinical trial approval for an mRNA vaccine for economic animals in China.

The vaccine targets swine epidemic diarrhea, a highly contagious disease causing severe symptoms like diarrhea, vomiting, and dehydration in pigs, with high mortality rates in newborn piglets.

The mRNA vaccine offers advantages in development efficiency, immune efficacy, and biosafety compared to traditional vaccines by precisely encoding key antigens to stimulate immune response.